Stockscreener 앱 받기
7.76
3.05%
0.23
시간 외 거래:
7.80
0.04
+0.52%
Sellas Life Sciences Group Inc 주식(SLS)의 최신 뉴스
SLS Stock Tests $5 Again: Retail Targets ‘No’ Vote On 20M Share Dilution Push Before AML Trial Results - Stocktwits
SLS Stock Hits Over 3-Year High As AML Drug Trial Nears Final Readout — Wall Street Sees 30% More Upside - Stocktwits
SLS Stock Jumps Premarket: CEO Says GPS AML Data Has ‘Very Good Chance’ To Beat Earlier Survival Outcomes - Stocktwits
SLS Stock Falls Premarket: CEO Touts GPS Leukemia Strategy, But Investors Stay Cautious As AML Trial Nears Readout - Stocktwits
SLS Stock Jumps Overnight: ‘Potent’ AML Drug Data Ahead Of Cancer Summit Fuels Fresh Momentum - Stocktwits
SLS Stock Gains Momentum: NVDA, MSFT Investor Loads Up Ahead Of AML Trial Milestone Trigger - Stocktwits
SLS Stock Rises Overnight: Traders Rally Behind Jim Cramer's 'Two Thumbs Up' Call Ahead Of Key AML Readout - Stocktwits
SLS Stock Sparks Retail Buzz Ahead of AACR Presentation On Experimental Cancer Therapy - Stocktwits
SLS CEO Angelos Stergiou Highlights Extended Capital Runway To Pursue Key Milestones, Growth Opportunities – A Look At The Important Numbers - Stocktwits
SLS Stock Pops Big After Hours On Imminent Leukemia Trial Data Readout Optimism - Stocktwits
SLS stock jumps overnight: CEO doubles down on ‘steadfast’ confidence in AML drug and pushes for 20M share plan approval - MSN
SLS stock slides premarket: Traders brace for key arbitration ruling in GPS China payment dispute - MSN
SLS Stock Rallies Ahead Of AML Trial Readout — ‘Pharma Bro’ Martin Shkreli Says He’s Still ‘Very Bearish,’ Predicts Drug Will Fail - Stocktwits
Why did ARM, SLS, EBAY stocks surge to 52-week highs? - MSN
SELLAS Life Sciences Group (SLS) price target increased by 15.38% to 10.20 - MSN
SLS Stock Extends Rally Overnight: CEO Says ‘Bullish’ Leukemia Data Could Drive NCCN Recognition For GPS - Stocktwits
SLS Stock’s Red-Hot Streak Draws Rising Short Bets — Retail Traders Are Now Betting On A Big Pharma Buyout - Stocktwits
SLS Stock Slides Premarket: Traders Brace For Key Arbitration Ruling In GPS China Payment Dispute - Stocktwits
Sellas Life Sciences Draws Significant Retail Buzz As Traders Eye REGAL Phase 3 Catalyst – SLS Stock Soars 15% - Stocktwits
Sellas Life Sciences draws significant retail buzz as traders eye REGAL phase 3 catalyst – SLS stock soars 15% - MSN
SLS stock extends rally overnight: CEO says 'bullish' leukemia data could drive NCCN recognition for GPS - MSN
SLS Stock Takes A Breather After Big Run: Traders Eye AML Summit Featuring Advisor For Clues On Trial Readout - Stocktwits
2.60%
0.94%
자본화:
|
볼륨(24시간):